Abstract
Drug prices are regulated in a legal framework that organizes the negotiation between pharmaceutical firms and a third-party payer responsible for healthcare reimbursement. This regulation aims at compensating for market failures associated with drug specificities. Explicit economic reasoning through the so-called health technology assessment framework is increasingly embedded in the institutional and administrative process of the evaluation procedure leading to market access, pricing and reimbursement for new drugs.
This is a preview of subscription content, log in via an institution to check access.
References
Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941–973
Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki P, Nasser M, Xerri B (2009) Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 87:339–367
Drummond M, Sculpher M, Claxton K, Stoddart G , Torrance G (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, New York
Franken M, Heintz E, Gerber-Grote A, Raftery J (2016) Health economics as rhetoric: the limited impact of health economics on funding decisions in four European countries. Value Health 19:951–956
Gerber-Grote A, Sandmann G, Zhou M, Thoren T, Schwalm A, Weigel C, Balg C, Mensch A, Mostardt S, Seidl A, Lhachimi K (2014) Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty? Z Evid Fortbild Qual Gesundhwes 108:390–396
Grossman M (1972) On the concept of health capital and the demand for health. J Polit Econ 80:223–255
Heintz E, Gerber-Grote A, Ghabri S, Hamers F, Prevolnik Rupel V, Slabe-Erker R, Davidson T (2016) Is there a European view on health economic evaluation? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. PharmacoEconomics 34:59–76
Hurley J (2000) An overview of the normative economics of the health sector. In: Culyer A, Newhouse J (eds) Handbook of health economics. Elsevier, Amsterdam, pp 55–118
ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Sullivan S, Mauskopf J et al (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17:5–14
Klingler C, Shah M, Barron J, Wright S (2013) Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German efficiency frontier approach. Health Policy 109:270–280
Mauskopf J (1998) Prevalence-based economic evaluation. Value Health 1:251–259
Mauskopf J (2014) Budget-impact analysis. In: Culyer A (ed) Encyclopedia of health economics, vol 1. Elsevier, Amsterdam, pp 98–107
Mauskopf J, Earnshaw S (2016) A methodological review of US budget-impact models for new drugs. PharmacoEconomics 34:1111–1131
McCabe C, Claxton K, Culyer A (2008) The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 26:733–744
Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64
Morris S, Devlin N, Parkin D (2007) Economic analysis in health care. Wiley, New York
Rice T, Rosenau P, Unruh L, Barnes A, Saltman R, van Ginneken E (2013) United States of America: health system review. Health Syst Transit 15:70–80
Sorenson C, Chalkidou K (2012) Reflections on the evolution of health technology assessment in Europe. Health Econ Policy Law 7:25–45
Walton S, Basu A, Mullahy J, Hong S, Schumock G (2017) Measuring the value of pharmaceuticals in the US health system. PharmacoEconomics 35:1–4
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this entry
Cite this entry
Josselin, JM., Rachet Jacquet, L., Raimond, V., Rochaix, L. (2017). Drug Price Regulation. In: Marciano, A., Ramello, G. (eds) Encyclopedia of Law and Economics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7883-6_714-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7883-6_714-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7883-6
Online ISBN: 978-1-4614-7883-6
eBook Packages: Springer Reference Economics and FinanceReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences
Publish with us
Chapter history
-
Latest
Drug Price Regulation- Published:
- 27 November 2020
DOI: https://doi.org/10.1007/978-1-4614-7883-6_714-2
-
Original
Drug Price Regulation- Published:
- 17 April 2017
DOI: https://doi.org/10.1007/978-1-4614-7883-6_714-1